Vifor Pharma has struck a deal to buy a priority review voucher (PRV). The PRV entitles Vifor to a speedy review at the FDA, but the Swiss drugmaker is yet to say how it will use the voucher.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,